Hai T T, Nelson D, Pereira D, Srnak A
Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, IL 60073.
Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):923-31. doi: 10.3109/10731199409117931.
By employing proprietary polymerization agents possessing specific binding groups and by completing diaspirin crosslinked hemoglobin (DCLHb) polymerization under specific conditions, we have selectively achieved the following objectives: (1) the P50 was adjusted to the physiologic range or left- or right-shifted; (2) the surface of DCLHb was modified ("decorated"); (3) DCLHb was polymerized but not decorated; (4) DCLHb was polymerized and decorated; or (5) DCLHb was site-specifically modified and polymerized.
通过使用具有特定结合基团的专有聚合剂，并在特定条件下完成双阿司匹林交联血红蛋白（DCLHb）的聚合，我们有选择地实现了以下目标：（1）将P50调整到生理范围或向左或向右移动；（2）修饰（“装饰”）DCLHb的表面；（3）使DCLHb聚合但不进行修饰；（4）使DCLHb聚合并进行修饰；或（5）对DCLHb进行位点特异性修饰并聚合。
